Company Info
| Year Established: | 2021 |
Contacts
| Primary: | Terry Connolly, Ph.D. President & CEO |
Company Description
K36's mission is to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics for the benefit of cancer patients worldwide.
